Diabetes: Risks of strict glycaemic control in diabetic nephropathy

Nature Reviews Nephrology 11, 5 (2015). doi:10.1038/nrneph.2014.209 Authors: Martin H. de Borst & Gerjan Navis A 6-year follow-up study of the ADVANCE trial participants reports that intensive glycaemic control is renoprotective—but does not reduce mortality—in patients with type 2 diabetes mellitus. By contrast, a post hoc analysis of the ACCORD trial suggests that intensive glycaemic control might increase mortality in patients with diabetic nephropathy.
Source: Nature Reviews Nephrology - Category: Urology & Nephrology Authors: Tags: News and Views Source Type: research